Stonepine Capital Management LLC Makes New $618,000 Investment in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Stonepine Capital Management LLC bought a new position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 182,317 shares of the company’s stock, valued at approximately $618,000. Stonepine Capital Management LLC owned about 0.12% of Xeris Biopharma at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. NewEdge Advisors LLC purchased a new stake in Xeris Biopharma in the fourth quarter worth $34,000. R Squared Ltd purchased a new position in shares of Xeris Biopharma in the fourth quarter valued at $42,000. Cibc World Markets Corp purchased a new position in shares of Xeris Biopharma in the fourth quarter valued at $44,000. Raymond James Financial Inc. purchased a new position in shares of Xeris Biopharma in the fourth quarter valued at $45,000. Finally, Aquatic Capital Management LLC purchased a new position in shares of Xeris Biopharma in the fourth quarter valued at $50,000. 42.75% of the stock is owned by hedge funds and other institutional investors.

Xeris Biopharma Stock Performance

NASDAQ:XERS opened at $4.88 on Friday. The firm has a market capitalization of $763.16 million, a price-to-earnings ratio of -10.84 and a beta of 1.10. Xeris Biopharma Holdings, Inc. has a 52-week low of $1.86 and a 52-week high of $6.07. The stock has a fifty day moving average of $4.72 and a 200 day moving average of $3.91.

Xeris Biopharma (NASDAQ:XERS) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.01. The business had revenue of $57.80 million for the quarter, compared to the consensus estimate of $57.61 million. Equities analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Xeris Biopharma news, insider Beth Hecht sold 40,000 shares of Xeris Biopharma stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $5.43, for a total transaction of $217,200.00. Following the completion of the sale, the insider now owns 1,353,510 shares of the company’s stock, valued at $7,349,559.30. The trade was a 2.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 6.47% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Craig Hallum lifted their price target on Xeris Biopharma from $5.00 to $6.50 and gave the company a “buy” rating in a research report on Friday, March 7th. Oppenheimer lifted their price target on Xeris Biopharma from $6.00 to $7.00 and gave the company an “outperform” rating in a research report on Friday, May 9th. Piper Sandler reiterated a “neutral” rating and issued a $4.00 price target (up from $3.00) on shares of Xeris Biopharma in a research report on Friday, March 7th. Jefferies Financial Group reiterated a “buy” rating and issued a $6.00 price target (up from $4.00) on shares of Xeris Biopharma in a research report on Wednesday, January 29th. Finally, Leerink Partners lifted their price objective on Xeris Biopharma from $5.00 to $6.00 and gave the company an “outperform” rating in a research note on Friday, March 7th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $6.25.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.